Oragenics, Inc. (OGEN)
AMEX$0.2861
Market Cap
$3.61M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
751 of 924
Rank in Industry
426 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
OGEN Insider Trading Activity
OGEN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,319 | 2 | 100 |
Related Transactions
| DUNTON ALAN W | director | 0 | $0 | 1 | $24 | $-24 |
| Telling Fred | director | 0 | $0 | 1 | $1,295 | $-1,295 |
About Oragenics, Inc.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to …
Insider Activity of Oragenics, Inc.
Over the last 12 months, insiders at Oragenics, Inc. have bought $0 and sold $1,319 worth of Oragenics, Inc. stock.
On average, over the past 5 years, insiders at Oragenics, Inc. have bought $214,785 and sold $1.36M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,084 shares for transaction amount of $2,884 was made by Telling Fred () on 2022‑06‑17.
List of Insider Buy and Sell Transactions, Oragenics, Inc.
| 2024-12-06 | Sale | Telling Fred | director | 3,597 0.0303% | $0.36 | $1,295 | -19.62% | |
| 2024-12-06 | Sale | DUNTON ALAN W | director | 66 0.0006% | $0.36 | $24 | -19.62% | |
| 2023-11-30 | Sale | Telling Fred | director | 3,500 0.3216% | $3.57 | $12,488 | -65.64% | |
| 2022-12-30 | Sale | KOSKI ROBERT C | director | 42,357 0.1151% | $0.11 | $4,469 | -45.61% | |
| 2022-12-29 | Sale | KOSKI ROBERT C | director | 36,648 0.1% | $0.11 | $3,885 | -48.03% | |
| 2022-12-15 | Sale | KOSKI ROBERT C | director | 140,497 0.636% | $0.18 | $24,699 | -66.33% | |
| 2022-12-14 | Sale | KOSKI ROBERT C | director | 29,503 0.1329% | $0.17 | $5,163 | -66.37% | |
| 2022-12-09 | Sale | KOSKI ROBERT C | director | 48,795 0.2475% | $0.20 | $9,613 | -69.51% | |
| 2022-12-08 | Sale | KOSKI ROBERT C | director | 13,036 0.0671% | $0.20 | $2,607 | -69.91% | |
| 2022-11-30 | Sale | KOSKI ROBERT C | director | 200,000 0.9841% | $0.19 | $38,220 | -70.87% | |
| 2022-11-29 | Sale | KOSKI ROBERT C | director | 200,000 0.9903% | $0.19 | $38,460 | -69.83% | |
| 2022-06-17 | Telling Fred | 10,084 0.0743% | $0.29 | $2,884 | -47.09% | |||
| 2022-05-23 | Telling Fred | director | 82,173 0.6123% | $0.29 | $23,780 | -31.79% | ||
| 2022-05-20 | Telling Fred | 65,718 0.4799% | $0.28 | $18,638 | -29.48% | |||
| 2022-05-19 | Telling Fred | director | 56,806 0.4106% | $0.28 | $15,945 | -29.29% | ||
| 2022-05-18 | Telling Fred | 15,303 0.1028% | $0.26 | $3,994 | -22.71% | |||
| 2022-03-30 | Telling Fred | director | 183,838 1.7008% | $0.36 | $66,053 | -34.17% | ||
| 2022-03-29 | Sullivan Michael O'Keefe | Interim PEO, CFO | 20,000 0.1782% | $0.35 | $6,922 | -31.59% | ||
| 2021-12-31 | KOSKI ROBERT C | director | 799,100 9.7531% | $0.47 | $378,773 | -26.08% | ||
| 2021-12-30 | KOSKI ROBERT C | director | 200,900 2.3268% | $0.45 | $90,365 | -23.29% |
Total: 137
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Telling Fred | director | 34748 0.2764% | $9,979.63 | 15 | 2 | <0.0001% |
| DUNTON ALAN W | director | 25623 0.2038% | $7,358.93 | 1 | 16 | <0.0001% |
| KIRK RANDAL J | 10 percent owner | 14481089 115.2026% | $4.16M | 3 | 0 | |
| HAWES GEORGE T | 10 percent owner | 10857235 86.3735% | $3.12M | 5 | 19 | |
| HILLMAN JEFFREY D | Director | 4202394 33.4317% | $1.21M | 1 | 2 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $3.75M | |
$296,936 | 37 | -18.12% | $4.42M | |
$1,616,354 | 20 | -12.22% | $3.22M | |
Oragenics, Inc. (OGEN) | $960,082 | 17 | -6.29% | $3.61M |
$1,558,469 | 16 | -26.98% | $4.4M |
OGEN Institutional Investors: Active Positions
| Increased Positions | 13 | +76.47% | 100,731 | +61.17% |
| Decreased Positions | 5 | -29.41% | 30,215 | -18.35% |
| New Positions | 10 | New | 94,585 | New |
| Sold Out Positions | 2 | Sold Out | 20,905 | Sold Out |
| Total Postitions | 25 | +47.06% | 235,182 | +42.82% |
OGEN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Xtx Topco Ltd | $11.00 | 0.3% | 38,925 | +38,925 | New | 2024-12-31 |
| Geode Capital Management, Llc | $11.00 | 0.3% | 38,483 | +2,762 | +7.73% | 2024-12-31 |
| Blackrock, Inc. | $6.00 | 0.16% | 21,059 | 0 | 0% | 2024-12-31 |
| Gsb Wealth Management, Llc | $6.00 | 0.16% | 20,202 | 0 | 0% | 2024-12-31 |
| Lionsbridge Wealth Management Llc | $6.00 | 0.15% | 20,000 | 0 | 0% | 2024-12-31 |
| Two Sigma Investments, Lp | $6.00 | 0.15% | 19,671 | +19,671 | New | 2024-12-31 |
| Hrt Financial Lp | $5.00 | 0.14% | 18,640 | -9,278 | -33.23% | 2024-12-31 |
| Two Sigma Securities, Llc | $5.00 | 0.13% | 16,966 | +16,966 | New | 2024-12-31 |
| Hbk Sorce Advisory Llc | $4.00 | 0.11% | 13,626 | +13,626 | New | 2024-12-31 |
| Warberg Asset Management Llc | $3.00 | 0.08% | 10,001 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.